Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status

Breast Cancer Research and Treatment

Volumn 97, Issue 1, 2006, Pages 49-55

  Xu, Ye ^a   Yao, Lihua ^a   Li, Hongxia ^a   Ouyang, Tao ^a   Li, Jinfeng ^a   Wang, Tianfeng ^a   Fan, Zhaoqing ^a   Lin, Benyao ^a   Lu, Youyong ^a   Larsson, Olle ^b   Xie, Yuntao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; erbB2 mRNA; Plasma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MAMMAGLOBIN; MESSENGER RNA; PROGESTERONE RECEPTOR; RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; ERBB2 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; PATIENT MONITORING; PHENOTYPE; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UTEROGLOBIN;

EID: 33646721093     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9086-7     Document Type: Article

References (29)

1. Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen W, Sellers TA, Kushi LH, Ruan Z, Bostick RM, Jin F, Zheng W: Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 87(2): 295-300, 2000
2. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352(9132): 930-942, 1998
3. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, Tanner M, Tirkkonen M, Isola J: Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 63(24): 8861-8868, 2003
4. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS: Cyclin E and survival in patients with breast cancer. N Engl J Med 347(20): 1566-1575, 2002
5. Johnson PJ, Lo YM: Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 48(8): 1186-1193, 2002
6. Beau-Faller M, Gaub MP, Schneider A, Ducrocq X, Massard G, Gasser B, Chenard MP, Kessler R, Anker P, Stroun M, Weitzenblum E, Pauli G, Wihlm JM, Quoix E, Oudet P: Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 105(3): 361-370, 2003
7. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareno E, Colas A, Espana P, Bonilla F: Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 8(12): 3761-3766, 2002
8. Lo YM, Chiu RW: The Biology and Diagnostic Applications of Plasma RNA. Ann N Y Acad Sci 1022: 135-139, 2004
9. Chan AK, Chiu RW, Lo YM: Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem 40(Pt 2): 122-130, 2003
10. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P: Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 6(10): 3823-3826, 2000
11. Dasi F, Lledo S, Garcia-Granero E, Ripoll R, Marugan M, Tormo M, Garcia-Conde J, Alino SF: Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest 81(5): 767-769, 2001
12. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2): 127-137, 2001
13. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34(6): 791-808, 1998
14. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S: Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 79(4): 216-223, 2002
15. Hartmann LC, Ingle JN, Wold LE, Farr GH, Jr, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 74(11): 2956-2963, 1994
16. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9(3): 923-930, 2003
17. Zehentner BK, Carter D: Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 37(4): 249-257, 2004
18. Zach O, Kasparu H, Wagner H, Krieger O, Lutz D: Mammaglobin as a marker for the detection of tumor cells in the peripheral blood of breast cancer patients. Ann N Y Acad Sci 923: 343-345, 2000
19. Grunewald K, Haun M, Urbanek M, Fiegl M, Muller-Holzner E, Gunsilius E, Dunser M, Marth C, Gastl G: Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab Invest 80(7): 1071-1077, 2000
20. Nilsson G, Skytting B, Xie Y, Brodin B, Perfekt R, Mandahl N, Lundeberg J, Uhlen M, Larsson O: The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 59(13): 3180-3184, 1999
21. Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, Lo ES, Rainer TH, Johnson PJ, Lo YM: Presence of filterable and non-filterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 48(8): 1212-1217, 2002
22. Fleischhacker M, Beinert T, Ermitsch M, Seferi D, Possinger K, Engelmann C, Jandrig B: Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci 945: 179-188, 2001
23. Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1(8377): 588-591, 1984
24. Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, Provencio M, Espana P, Bonilla F: Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 7(9): 2821-2825, 2001
25. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K: ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61(5): 1890-1895, 2001
26. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101(25): 9393-9398, 2004
27. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24): 8152-8162, 2004
28. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20(16): 3404-3412, 2002
29. Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V: Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14(6): 849-855, 2003